5
Clinical Summary
The AMPLATZER™ Septal Occluder was evaluated in a multi-center, non-randomized, pivotal
study comparing the device to surgical closure of atrial septal defects (ASDs); 423 patients
received 433 devices with a total device exposure of 911.5 years. Individual patient exposure to
the device averaged 25.6 months (ranging from 0 to 38.9).
A Registry group was also studied to evaluate the device in patients with other conditions
appropriate for device closure. Forty-eight (48) patients with Fenestrated Fontan (communication
in the baffle with at least 5 mm distance from the free atrial wall and central venous pressure less
than 15 mm Hg) were enrolled in the study.
Deaths
There was one non-device or procedure-related death reported in the pivotal study, and no deaths
were reported in the Fenestrated Fontan Registry Group.
Observed Adverse Events
Pivotal Clinical Study
Table 1. Adverse Events – Pivotal Study
AMPLATZER™
Patients
Surgical
Control
Patients
p-value
Major Adverse Events
Cardiac arrythmia requiring major treatment
2/442 (0.5%)
0/154 (0.0%)
1.00
Device embolization with surgical removal
3/442 (0.7%)
0/154 (0.0%)
0.57
Device embolization with percutaneous removal
1/442 (0.2%)
0/154 (0.0%)
1.00
Delivery system failure
1/442 (0.2%)
0/154 (0.0%)
1.00
Pericardial effusion with tamponade
0/442 (0.0%)
3/154 (1.9%)
0.017
Pulmonary edema
0/442 (0.0%)
1/154 (0.6%)
0.26
Repeat surgery
0/442 (0.0%)
2/154 (1.3%)
0.066
Surgical wound adverse events
0/442 (0.0%)
2/154 (1.3%)
0.066
Total Major Adverse Events (Patients)
7/442 (1.6%)
8/154 (5.2%)
0.030
Minor Adverse Events
Anemia
0/442 (0.0%)
1/154 (0.6%)
0.26
Allergic reaction (drug)
2/442 (0.5%)
0/154 (0.0%)
1.00
Atelectasis
0/442 (0.0%)
1/154 (0.6%)
0.26
Cardiac arrythmias minor treatment
15/442 (3.4%)
9/154 (5.8%)
0.23
Device embolization with percutaneous removal
1/442 (0.2%)
0/154 (0.0%)
1.00
Extremity tingling/numbness
1/442 (0.2%)
0/154 (0.0%)
1.00
Headaches/possible TIA
2/442 (0.5%)
0/154 (0.0%)
1.00
Delivery system failure
2/442 (0.5%)
0/154 (0.0%)
1.00
Pericardiotomy syndrome
0/442 (0.0%)
2/154 (1.3%)
0.066
Pericardial effusion
0/442 (0.0%)
6/154 (3.9%)
<0.001
Pleural effusion
0/442 (0.0%)
1/154 (0.6%)
0.26
Pneumothorax
0/442 (0.0%)
3/154 (1.9%)
0.017
Staph infection
0/442 (0.0%)
1/154 (0.6%)
0.26
Surgical wound adverse events
0/442 (0.0%)
1/154 (0.6%)
0.26
100092311_ASD.book Page 5 Monday, January 6, 2014 11:00 AM